Drug Type Small molecule drug |
Synonyms 101 PGC 005, 101PGC005, 101PGC005 (005) |
Target |
Mechanism GR antagonists(Glucocorticoid receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization 101 Therapeutics Ltd.Startup |
Active Organization 101 Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
Drug intoxication | Phase 1 | IN | 101 Therapeutics Ltd.Startup | 29 Oct 2022 |
Post Acute COVID 19 Syndrome | Phase 1 | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
Dengue | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
HCoV-OC43 infection | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
Leishmaniasis | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |
Zika Virus Infection | Preclinical | - | 101 Therapeutics Ltd.Startup | 26 Aug 2022 |